Overview of the Current Role of Stereotactic Body Radiotherapy in the Treatment of Unfavorable Intermediate- and High-Risk Prostate Cancer
Maris Mezeckis, Danny Vesprini, Vladyslav Buryk, Leszek Miszczyk and Egils Vjaters
Stereotactic body radiotherapy (SBRT) is well accepted for low- and intermediate-favorable risk prostate cancer. Available evidence about the application of SBRT in unfavorable- and high-risk prostate cancer is less solid. During last year’s multiple variations in treatment, techniques have been reported making comparisons more complicated. This review’s objective is to review current evidence in application of SBRT in intermediate unfavourable and high-risk prostate cancer and to outline variations in SBRT treatment techniques and relevant results.
Keywords: Intermediate unfavorable, high-risk prostate cancer, SBRT, stereotactic body radiotherapy
Full Text (IP)
Purchase Article (PDF)